Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6264 | Ordered by Date (descending)
1 2 3 ... 61 62 63  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Dyne Therapeutics–Atlas Venture: investment, 201904 financing round Series A totalling $50m incl founding investor Atlas Venture 2019-04-03
Dyne Therapeutics–Forbion: investment, 201904 financing round Series A totalling $50m incl co-investor Forbion 2019-04-03
Dyne Therapeutics–MPM Capital: investment, 201904 financing round Series A totalling $50m incl co-investor MPM Capital 2019-04-03
Dyne Therapeutics–SEVERAL: investment, 201904 financing round Series A $50m from founding investor Atlas Venture plus Forbion + MPM Capital 2019-04-03
LabCorp–Qiagen: molecular companion diagnostics, 201904– collab LabCorp joins Qiagen’s Day-One Lab Readiness program 2019-04-03
Rave LLC–Bruker Corp: investment, 201904 acquisition €na by Bruker 2019-04-03
Khloris Biosciences–Bayer: investment, 201904 seed financing €na from Leaps by Bayer 2019-04-02
IFM Therapeutics–Novartis: investment, 201904– acquisition 100% of IMF Tre for upfront payment + milestones ANNOUNCED 2019-04-01
Karuna–Alexandria Real Estate: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Alexandria Venture Investments 2019-04-01
Karuna–ARCH Venture: investment, 201903–201904 financing round Series B totalling $80m incl exisiting + lead investor ARCH Venture Partners 2019-04-01
Karuna–Eventide Asset Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Eventide 2019-04-01
Karuna–Fidelity: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Fidelity Management & Research 2019-04-01
Karuna–Nan Fung: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Pivotal BioVenture Partners 2019-04-01
Karuna–Partner Fund Management: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Partner Fund Management 2019-04-01
Karuna–PureTech Health: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor PureTech Health 2019-04-01
Karuna–Sands Capital: investment, 201903–201904 financing round Series B totalling $80m incl co-investor Sands Capital 2019-04-01
Karuna–SEVERAL: investment, 201903–201904 financing round Series B $80m led by ARCH Venture Partners incl $5m debt conversion 2019-04-01
Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments 2019-04-01
Karuna–Wellcome Trust: investment, 201903–201904 financing round Series B totalling $80m incl exisiting investor Wellcome Trust 2019-04-01
Blueprint Medicines–SEVERAL: investment, 201903 public offering $300m+$45m with 4.055m+608k common shares at $74/share 2019-03-28
Inivata–Consilium: public relations, 201903 service existent by CSC 2019-03-28
Inivata–LifeSci: public relations, 201903 service existent IR by LifeSci Advisors 2019-03-28
Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA 2019-03-28
Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA 2019-03-28
Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners 2019-03-28
Selvita–Trout Group: public relations, 201903 service existent media relations + IR by The Trout Group 2019-03-28
Univ College London–ArcherDx: PCR technology, 201903– collab €na use of AMP technology in UCL-sponsored UK lung cancer diagnostics TRACERx study 2019-03-28
H4Orphan Pharma–Cerenis: investment, 201903– excl negotations for potential merger w Cerenis owning 59% of combined company 2019-03-27
Evotec–Mark Foundation: investment, 201903–202102 research funding for two years €na by Mark Foundation with potential financial returns 2019-03-26
Brammer Bio–Thermo Fisher: investment, 201903– acquisition $1.7b in cash from Ampersand Capital Partners + Founders ANNOUNCED 2019-03-24
Hookipa–SEVERAL: investment, 201903– IPO up to $86.3m at Nasdaq FILED 2019-03-22
Sherlock Biosciences–SEVERAL: investment, 201903 first financing round $35m incl $17.5m grant + an investment from Open Philantrophy Project 2019-03-21
Verona Pharma–ICR: public relations, 201903 service existent by ICR in US 2019-03-21
Atlatl–Miltenyi Biotec: CliniMACSProdigy platform, 201903– collab co-founding of Atlatl-Macs Center for Gene + Cell Therapy in Shanghai 2019-03-20
Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) 2019-03-20
Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares 2019-03-20
Oncimmune–Qiagen: investment, 201903 up to 1.34% shareholding for Qiagen after Oncimmune’s acquisition of Protagen 2019-03-19
Protagen–Oncimmune: investment, 201903 acquisition of Portagen for up to £4.11m in up to 2.636m ordinary shares 2019-03-19
Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp 2019-03-14
Ovation.io–Borealis Ventures: investment, 201903 financing round Series A totalling $5m incl new + co-investor Borealis Ventures 2019-03-14
Ovation.io–Madrona Venture: investment, 201903 financing round Series A totalling $5m incl lead investor Madrona Venture Group 2019-03-14
Ovation.io–SEVERAL: investment, 201903 financing round Series A $5m led by Madrona Venture + incl Borealis Ventures et al. 2019-03-14
Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectos by MolMed for three new indications 2019-03-13
Biogen–Fujifilm: biologics contract manfuacturing, 201903– supply manufacturing of biologicals for Biogen incl Tysabri 2019-03-12
Biogen–Fujifilm: investment, 201903– acquisition up to $890m in cash of Biogen’s Biologics Manufacturing Site in Hillerød Denmark 2019-03-12
Osage Partners–SEVERAL: investment, 201903 closing $273m of Osage Univ Partners III LP venture fund 2019-03-12
Oxford BioMedica–Microsoft: bioinformatics, 201903–202102 collab r+d using MS Azure cloud + machine learing to optimise gene therapy vectors 2019-03-12
AstraZeneca–Seres Therapeutics: microbiomics, 201903–202202 collab research 3y $20m + research funding for microbiomics to support I-O therapies 2019-03-11
InventisBio–Lilly: investment, 201903 financing round Series C totalling $70m incl existing + co-investor Lilly Asia Ventures 2019-03-11
InventisBio–OrbiMed: investment, 201903 financing round Series C totalling $70m incl existing + co-investor OrbiMed Asia 2019-03-11
InventisBio–SEVERAL: investment, 201903 financing round Series C $70m co-led by Advantech Capital + CMBI 2019-03-11
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Erasca–Andreessen Horowitz: investment, 201903 financing round Series A extension by $22m to $64m incl new investor Andreessen Horowitz 2019-03-05
Erasca–ARCH Venture: investment, 201903 financing round Series A extension by $22m to $64m incl new investor ARCH Venture Partners 2019-03-05
Erasca–Reneo Capital: investment, 201903 financing round Series A extension by $22m to $64m incl new investor Reneo Capital 2019-03-05
Erasca–SEVERAL: investment, 201903 financing round Series A extension by $22m to $64m incl new investors ARCH + Andreessen Horowitz + Reneo Capital 2019-03-05
Ascendis Pharma–SEVERAL: investment, 201903– public offering $400m+$60m ADSs 2019-03-04
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
JnJ–AdoRx: adenosine receptor antagonists, 201902– collab developm + excl option €na lung cancer drugs with JnJ Innovation 2019-02-28
Mersana–SEVERAL: investment, 201902–201903 Public Offering $97.8m with 24.44m shares common stock at $4/share 2019-02-28
Sarepta Therapeutics–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene 2019-02-28
CN Innovations–MIT: organ-on-a-chip technology, 201902– license excl for organ-on-a-chip with human tissues fomr up to 10 organs for CN Bio 2019-02-27
Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America 2019-02-27
Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market 2019-02-27
MeiraGTx–683 Capital Management: investment, 201902 private placement totalling $80m incl co-investor 683 Capital Management 2019-02-27
MeiraGTx–JnJ: investment, 201902 private placement totalling $80m incl $40m from lead investor JJDC Inc 2019-02-27
MeiraGTx–Orbimed: investment, 201902 private placement totalling $80m incl co-investor Orbimed Advisors 2019-02-27
MeiraGTx–Perceptive Advisors: investment, 201902 private placement totalling $80m incl co-investor Perceptive Advisors 2019-02-27
MeiraGTx–SEVERAL: investment, 201902 private placement $80m with 5.8m ordinary shares at $13.8/share led by JJDC Inc 2019-02-27
Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck 2019-02-27
Hookipa–Invus Group: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Invus 2019-02-26
Hookipa–Redmile Group: investment, 201902 financing round Series D totalling €33.2m incl new + lead investor Redmile Group 2019-02-26
Hookipa–Samsara BioCapital: investment, 201902 financing round Series D totalling €33.2m incl new + co-investor Samsara BioCapital 2019-02-26
Hookipa–SEVERAL: investment, 201902 financing round Series D €33.2m ($37.4m) led by Redmile Group + incl Invus + Samsara Capital et al. 2019-02-26
Samsara Therapeutics–Apollo Ventures: investment, 201902 seed financing round totalling €1m incl lead investor Apollo Ventures 2019-02-26
Samsara Therapeutics–Evotec: medicinal chemistry, 201902 supply service existent compound optimisationn by Evotec 2019-02-26
Samsara Therapeutics–SEVERAL: investment, 201902 seed financing round €1m led by Apollo Ventures 2019-02-26
General Electric–Danaher: investment, 201902– acquisition $21.4b in cash of biopharma business of GE Life Sciences ANNOUNCED 2019-02-25
Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche 2019-02-25
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Centerview Partners: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Cowen: financial services, 201902 supply financial advisor to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Goodwin Procter: legal services, 201902 supply legal counsel to Spark with regard to acquisition of Spark by Roche 2019-02-25
Spark Therapeutics–Roche: investment, 201902– acquisition $4.3b cash tender offer for all shares at $114.5/share ANNOUNCED 2019-02-25
AbbVie–Voyager Therapeutics: AAV technology, 201902– collab ww excl $65m upfront +>$1b milestones + royalties developm vectorised Abs for PD 2019-02-22
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner 2019-02-20
BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund 2019-02-20
BiomX–MacDougall Biomedical Communications: public relations, 201902 service existent by MacDougall 2019-02-20
BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al 2019-02-20
Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totallling €20m incl co-lead investor Inkef Capital 2019-02-20
Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totallling €20m incl co-lead investor Gilde Healthcare 2019-02-20
Calypso Biotech–JnJ: investment, 201902 financing round Series A totallling €20m incl co-investor JnJ Innovation JJDC 2019-02-20
Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totallling €20m incl co- + founding investor M Ventures 2019-02-20
Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital 2019-02-20
CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies 2019-02-19
S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch 2019-02-18
1 2 3 ... 61 62 63  next pagenext page



Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px

» top